Clinical Trials Logo

Relapsing Forms of MS clinical trials

View clinical trials related to Relapsing Forms of MS.

Filter by:
  • None
  • Page 1

NCT ID: NCT04948606 Terminated - Clinical trials for Relapsing Forms of MS

Exploring Diroximel Fumarate Real-world Experience in Canada and Israel

EXPER-CA/IL
Start date: December 9, 2021
Phase:
Study type: Observational

The primary objective of the study is to characterize the persistence to therapy in participants with relapsing forms of multiple sclerosis (RMS) treated with diroximel fumarate (DRF) in routine clinical practice. The secondary objectives of the study are to assess short-term persistence to treatment; to assess long-term persistence on treatment; to assess the effect of DRF on relapses; to assess the impact of DRF on cognition; to assess the impact of DRF on participant reported outcomes (PROs); to assess the impact of DRF on disability; to assess treatment satisfaction with DRF; to explore the real-world safety profile of DRF (i.e., gastrointestinal [GI] tolerability, lymphocyte dynamics, adverse events [AEs] leading to discontinuation, and serious adverse events [SAEs].

NCT ID: NCT04746976 Terminated - Clinical trials for Relapsing Forms of MS

Study of Diroximel Fumarate in the Real-World Setting

Start date: March 1, 2021
Phase:
Study type: Observational

The primary objective of the study is to characterize the persistence to therapy in participants with relapsing forms of multiple sclerosis (RMS) treated with diroximel fumarate (DRF) in routine clinical practice. The secondary objectives of the study are to assess short-term persistence to treatment; to assess long-term persistence on treatment; to assess the effect of DRF on relapses; to assess the impact of DRF on cognition; to assess the impact of DRF on participant reported outcomes (PROs) and to explore the real-world safety profile of DRF (ie, gastrointestinal [GI] tolerability, lymphocyte dynamics, adverse events [AEs] leading to discontinuation, and serious adverse events [SAEs]).